NBIX’s Elagolix Moving Forward – Analyst Blog
Just recently, Neurocrine Bio (NBIX) presented results from the full twelve month analysis of the Petal-603 study, which includes data from the six months on treatment and six months follow-up period. Petal was a phase IIb...
Read More

